DURHAM, N.C. & SEATTLE--January 12, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and...
Cequent releases primate safety, efficacy data for oral FAP therapy
News | 02. 12. 2009
Cequent Pharmaceuticals
February 12, 2009
Cequent Pharmaceuticals this week unveiled non-human primate data demonstrating the safety and gene-silencing ability of its lead drug candidate, a treatment for familial adenomatous polyposis dubbed CEQ501, in what the company is calling the first proof of activity of an oral RNAi drug.
